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The efficiency of anticancer therapy is often restricted by the development of drug resistance. Here, we report that the doxorubicin (DOX)-
resistant MCF-7/Adr cells were more resistant to DOX-treatment than MCF-7 cells. However, an alternative treatment of DOX/TNF-α enhanced
the cytotoxic effect in multidrug resistant MCF-7/Adr cell line. Treatment of cells with TNF-α following doxorubicin (DOX) resulted in a
decrease of the activated Rel A/p65 in nuclei. Histone deacetylase 1 (HDAC1) was found to interact with Rel A/p65 in the complex, suggesting
that HDAC1 is involved in mediating nuclear export of Rel A/p65. The combined treatment of TNF-α/DOX also resulted in a significant decrease
of mRNA levels of anti-apoptotic genes, such as the cellular inhibitor of apoptosis-1 (c-IAP1), and the long isoform of B cell leukemia/lymphoma
x gene (Bcl-xL), leading to efficient induction of caspase-8 cleavage and cell death. In previous work, we demonstrated that TNF-α promotes
DOX-induced cell death and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Thus, we proposed that alternative
administration of TNF-α and DOX may be a new and efficient therapeutic strategy for patients that develop resistance to cytotoxic treatment.
© 2005 Elsevier B.V. All rights reserved.Keywords: Anti-apoptotic gene; Caspase-8; Histone deacetylase 1; Rel A/p65; Tumor necrosis factor-α1. Introduction
Tumor necrosis factor-α (TNF-α) is a glycoprotein that pos-
sesses antitumor activities against a wide range of tumor cell
lines, whereas nonmalignant cells are relatively resistant [1].
But its clinical application is limited by its severe systemic side
effects before therapeutic doses could be reached. Recently, the
feasibility of TNF-α as a biological response modifier was dem-
onstrated. Our clinical phase II and phase III trials showed that
systemic administration of TNF-α in combination with a chemo-
therapeutic agent DOX for lung tumors remarkably enhanced the
anti-tumor effect, as compared to the DOX treatment alone. In
total, 44% of the 133 patients exhibited complete or partial
remission of lung tumors in response to this combination therapy
strategy [2–4]. Since it has been approved by the Chinese SDA,
this innovative clinical application of TNF-α in combination with
DOX may offer great opportunities for cancer patients. Further-⁎ Corresponding author. Tel.: +86 21 50803248 1320; fax: +86 21 50803128.
E-mail address: yanjunlu@hotmail.com (Y. Lu).
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doi:10.1016/j.bbamcr.2005.12.008more, in the setting of hyperthermic isolated limb perfusion
(HILP), TNF-α in combination with melphalan appeared to be
very active against irresectable sarcomas and melanomas, tumors
known to be resistant against chemotherapy [5,6]. The results of
the combination TNF-α with other chemotherapeutic agents sug-
gest the synergistic anti-tumor effects in chemotherapy-resistant
tumors. However, the molecular basis for the combination treat-
ment has not been well elucidated.
TNF-α binding to its receptors and the active TNF-α receptor
complexes can interact with caspase-8 proteases via TRADD
and FADD to induce cell death, whereas NFκB activation in-
duced by TNF-α inhibits cell death [7]. The prototypical NFκB
complex, which responds to heterodimer of p50 and Rel A/p65
subunits, exists as the inactive dimmer sequestered in the cyto-
plasm. The activated NFκB heterodimer rapidly translocates
into the nucleus, where it engages the κB enhancer elements
and alters gene expressions. In fact, NFκB regulates a set of anti-
apoptotic genes including the members of the Bcl-2 family,
cellular inhibitors of apoptosis protein C (c-IAP 1 and 2), A20
and superoxide dismutase 2 (SOD2). These anti-apoptotic
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preventing cytotoxic actions induced by TNF-α stimulation [8].
The Doxorubicin (DOX)-resistant human breast cancer cell
line MCF-7/Adr displays cross-resistance to many chemothera-
peutic agents such as anthracyclines, taxol and some other drugs
[9]. Multidrug resistance in MCF-7/Adr cells is associated with
several different mechanisms including overexpression of P-
glycoprotein, glutathione s-transferase and glutathione peroxi-
dase [10].
DOX, a widely used anti-tumor agent, targets DNA topoi-
somerase II enzyme activity, which involves sequential DNA
binding, cleavage of DNA phosphodiester backbone and sub-
sequently causes DNA breaks. Our previous data suggested that
the abnormal progression of cell cycle is responsible for DOX-
induced cell death [11,12].
In previous work, we demonstrated that TNF-α promotes
the anti-cancer effect of DOX through suppressing the anti-
apoptotic activity of p21, and that a combined treatment TNF-
α/DOX is an effective chemotherapeutic strategy for p53-defi-
cient tumor cells [13]. In this study, using MCF-7 and its
multidrug resistant derivative cell line MCF-7/Adr, we demon-
strated the treatment with TNF-α/DOX strongly increased
MCF-7/Adr cells' sensitivity to cytotoxic treatment, which
was correlated with a down-regulation of NF-κB -mediated
anti-apoptotic gene expressions. This effect is dependent, at
least in part, on the cytoplasmic relocalization of NFκB/Rel
A/p65 induced by HDAC1.
2. Materials and methods
2.1. Cells and cell culture
Human breast cancer cell line MCF-7 cells and the doxorubicin-resistant
cell line MCF-7/Adr cells were cultured in Dulbecco's modified Eagle's min-
imum essential medium (Hyclone, Logan, UT) supplemented with 10% fetal
bovine serum (Hyclone, Logan, UT).
2.2. Measurement of cell death
Cells were seeded into 96-well microtiter plate and treated either with 24 h of
DOX (0.8 μg/ml) alone or with 24 h of DOX (0.8 μg/ml) and then 0.5 h of TNF-α
(500U/ml) treatment. Then, 10 μl of the CCK-8 solution is added to eachwell of the
plate and it was incubated for 2 h in the incubator (37 °C and 5% CO2) according to
the procedure of Cell Counting Kit-8 (Dojindo Laboratories, Tokyo, Japan). The
absorbance was measured at 450 nm using a microplate reader (BioTeK).
2.3. Western blotting and immunoprecipitation
The nuclear, whole-cell and cytoplasmic extracts from cells treated differ-
ently were prepared by the Nuclear Extract Kit (Active Motif, Carlsbad, CA).
The protein content of the cell lysate was determined by using the Bradford
calorimetric assaymethod (Bio-Rad, Richmond, CA). A 40-μg aliquot of the cell
lysate was resolved by 12% polyacrylamide-sodium lauryl sulfate gel electro-
phoresis and transferred to a Hybond-C Super membrane (Amersham, Buck-
inghamshire, UK). P65 and caspase-8 were detected with an antibody against
p65 (Upstate, USA) and an antibody against caspase-8 (Merck, USA), respec-
tively. Then the blot was incubated with a secondary antibody, IRDye 800
conjugated affinity purified anti-mouse or anti-rabbit IgG (Rockland Immuno-
chemicals, Inc., Gilbertsville, PA) and detected with Odyssey Infrared Imaging
System (LI-CDR Bioscienceces Co., Nebraska, USA). For immunoprecipita-
tion, a 500-μg aliquot of cell lysate was incubated at 4 °C with 2 μl of an
antibody against p65 (Upstate, USA) for 1 h, then vortexed completely at 4 °C,centrifuged and collected the precipitation, and washed with NP-40 buffer and
lysed with loading buffer to do Western Blotting analysis. HDAC1 was detected
with an antibody against HDAC1(Santa Cruz Biotechnology, USA).
2.4. RNA extraction and RT-PCR
Total RNA was extracted from MCF-7/Adr cells by using the RNeasy
kit (Qiagen) following the manufacturer's instructions. Five hundred to 10
ng of RNA was used to perform the semiquantitative PCR analysis by
using the RT-PCR system (Fermentas). PCR products were resolved by
agarose gel electrophoresis and visualized by staining with ethidium bro-
mide. Primers used for Bcl-xL, c-IAP1, and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were as follows: Bcl-xL, sense, 5′-GGAGCTGG-
TGGTTGACTTTCT-3′, and antisense, 5′-CCGGAAGAGTTCATTCACTA-
C-3′; c-IAP1, sense, 5′-AGGGAATTCATGCACAAAACTGCCTCCCA-3′,
and antisense, 5′-CTCCTCGAGGATGGCTTCAAGTGTTCAAC-3′; GAP-
DH, sense, 5-GGTCGTATTGGGCGCCTGGTCACC-3′, and antisense, 5′-
CACACCCATGACGAACATGGGGGC-3′.
2.5. Electrophoretic mobility shift assays
A 30-μl of annealing mixture containing 2 μl of each κB site oligonucleo-
tide (sense: 5′-agt tga ggg gac ttt ccc agg c-3′; antisense: 5′-gcc tgg gaa agt ccc
ctc aac t-3′) in 0.5 M NaCl was incubated 2 min at 80 °C then stopped the
heating and maintained in water bath until 35 °C. The above 8 μl of solution, 2
μl of 10× labeling Buffer and 2 μl IR Dye label solution (IRDye™ 800 labeling
kit, Odyssey, USA) were mixed, and the reaction proceeded for 5 min at 70 °C.
MCF-7/Adr cells untreated or with treatment of DOX (0.8 μg/ml) for 0.5, 2,
6 or 12 h were washed with ice-cold PBS, and then collected. The nuclear
extracts were prepared by the Nuclear Extract Kit (Active Motif, Carlsbad, CA),
and 5 μg aliquots of the extracts were preincubated with 1.5 μl of above labeled
oligonucleotide on ice for 30 min. The complexes were resolved on a 5%
polyacrylamide gel. The gel was scanned by Odyssey infrared imaging system.
3. Results
3.1. A combined treatment TNF-α/DOX alleviates the
resistance of MCF-7/Adr cells to cytotoxic treatment
The DOX-resistant human breast cancer cell line MCF-7/
Adr displays resistance to many chemotherapeutic agents. To
confirm this point we treated MCF-7 cells and its DOX resis-
tant derivatives MCF-7/Adr cells with DOX for 24 h. Data from
Fig. 1 showed that there were inherent differences between
MCF-7 cells and MCF-7/Adr cells as displayed by cell survival
curves. This result indicated that MCF-7/Adr cells were more
resistant to DOX than MCF-7 cells.
To explore a condition for a killing effect on multidrug
resistant MCF-7/Adr cells, we treated cells with DOX, and
then incubated the cells with TNF-α for 0.5 h (i.e., 24
h DOX, 0.5 h TNF-α). Interestingly, MCF-7/Adr cells were
more sensitive to the cytotoxic effect of this DOX-TNF-α
treatment than to that of a simple 24 h DOX treatment. Its
parental MCF-7 cells also showed more sensitive to this com-
bined therapy (Fig. 1). Together, our data suggest that MCF-7/
Adr cells displayed resistance to DOX-induced cell death, but
the treatment TNF-α/DOX reduced its resistance to cytotoxi-
city to the level of the parental cell line MCF-7. This observa-
tion led us to suggest that the alternative administration of
TNF-α with DOX may be a more effective protocol for the
therapeutic treatment of chemotherapeutic agent-resistant
tumors.
Fig. 2. DOX mediates to export Rel A/p65 from nucleus. (A) MCF-7/Adr cells
or (B) MCF-7 cells were treated with DOX (0.8 μg/ml) alone for 24 h, with
TNF-α (500U/ml) alone for 0.5 h, or 24 h of DOX (0.8 μg/ml) followed by
0.5 h of TNF-α (500 U/ml) treatment. The nuclear and cytoplasmic p65
expressions were determined by Western blot analysis.
Fig. 3. HDAC1 mediates Rel A/p65 translocation from the nucleus to the
cytoplasm after the treatment with DOX. (A) MCF-7/Adr cells treated with
DOX (0.8 μg/ml) for 0, 0.5, 2, 6, and 12 h. The nuclear and cytoplasmic p65
expressions were determined by Western blotting analysis. (B) Rel A/p65 was
immunoprecipitated from the nuclear extracts of MCF-7/Adr cells with DOX
(0.8 μg/ml) treatment for 0, 0.5, 2, 6 and 12 h. HDAC1 protein was detected by
Western blotting analysis in the complex. (C) Nuclear extracts from MCF-7/Adr
cells treated with DOX (0.8 μg/ml) for 0, 0.5, 2, 6, and 12 h were subjected to
electrophoretic mobility shift assay (EMSA) using IR Dye™ labeled κB
oligonucleotide.
Fig. 1. TNF-α/DOX alleviates the resistance of MCF-7/Adr cells to cytotoxic
treatment. The fractions of survival cells after 24 h of DOX (0, 0.1, 0.2, 0.4, 0.6,
0.8 μg/ml) treatment in MCF-7 cells (○) and MCF-7/Adr cells (□), or 24 h of
DOX (0.8 μg/ml) and then 0.5 h of TNF-α (500 U/ml) treatment in MCF-7 cells
(●) and MCF-7/Adr cells (■). Results represent the mean±S.D. of the three
determinations.
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line that underwent cell death induced by various apoptotic
stimuli did not display some of the distinct morphological
features characteristic of apoptosis such as nuclear shrinkage
and membrane blebbing. It was due to a partial deletion within
exon 3 of caspase-3 gene in MCF-7 cells.
3.2. HDAC1 mediated Rel A/p65 translocation from nucleus to
cytoplasm after treatment with DOX
Numerous reports indicate that NFκB plays an important
anti-apoptotic role in TNF-α induced apoptosis by acting as a
sequence-specific DNA binding transcription factor and in-
ducing a variety of anti-apoptotic gene expressions. To ex-
amine the biochemical events of the activated Rel A/p65 in
nuclei and the inactivated Rel A/p65 in cytoplasms in this
study, MCF7 and MCF-7/Adr cells were either untreated or
treated with TNF-α and with DOX alone or with TNF-α
following DOX treatment. The levels of nuclear and cyto-
plasmic Rel A/p65 were assessed by Western blotting analy-
sis with an antibody against Rel A/p65. As shown in Fig. 2A
and B, the nuclear Rel A/p65 was elevated in both cell lines
after TNF-α stimulation. In contrast, the nuclear activated Rel
A/p65 was much lower in the treatment with DOX (24 h)
alone or followed by a treatment with TNF-α. Moreover, the
amount of cytoplasmic Rel A/p65 likely corresponded to its
pattern in nuclei.
NFκB/Rel A is also activated by ionizing radiation and some
chemotherapeutic compounds, such as DOX, to translocate to
the nucleus. Study was next performed to examine the nuclear
Rel A/p65 after treatment with DOX for 0, 0.5, 2, 6, and 12 h in
MCF-7/Adr cells. The levels of nuclear Rel A/p65 were
assessed by immunoblotting in DOX-treatment time course.
As shown in Fig. 3A, DOX-induced nuclear Rel A/p65 was
accumulated and sustained in the peak after 2 h–6 h treatment
with DOX and then diminished.
Fig. 4. Treatment of TNF-α following DOX represses the expression of Bcl-xL
and c-IAP1. (A) MCF-7/Adr cells and (B) MCF-7 cells were treated with DOX
(0.8 μg/ml) alone for 24 h, with TNF-α (500 U/ml) alone for 0.5 h, or 24 h of
DOX (0.8 μg/ml) followed by 0.5 h of TNF-α (500 U/ml) treatment. The
semiquantitative PCR analysis was then performed in extracted RNA from
above treated cells using primers specific to human Bcl-xL, c-IAP1 or a
GAPDH control.
Fig. 5. Treatment of TNF-α following DOX potentiates the activation of
caspase-8. MCF-7/Adr cells were treated with DOX (0.8 μg/ml) alone for
24 h, with TNF-α (500 U/ml) alone for 0.5 h, and 24 h of DOX (0.8 μg/ml)
followed by 0.5 h of TNF-α (500 U/ml) treatment. The proteolysis of caspase-
8 was analyzed by immunoblotting using a specific antibody against cleaved
caspase-8.
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deacetylased, HDAC1,2 and 3 influence NF-κB activity
through direct or indirect interaction with Rel A/p65.
Those associations have been reported to regulate NF-κB's
DNA binding and nuclear export [15–17]. Consistent with
this hypothesis, immunoprecipitation experiments were car-
ried out as follows: MCF-7/Adr nuclear extracts were
immunoprecipitated with an antibody against p65 and then
HDAC1 protein was assessed by Western blotting analysis
in the complex, after treated with DOX for the time indi-
cated. The results in Fig. 3B demonstrated the treatment
with DOX induced Rel A/p65 association with HDAC1. In
contrast, TNF-α stimulation did not result in the increased
association of Rel A/p65 with HDAC1 at this time point
(data not shown). HADC2, HDAC3 proteins were also
checked by Western blotting analysis in p65 immunopreci-
pitated complex, no apparent difference observed. Electro-
phoretic mobility shift assays suggested that DOX treatment
resulted in the strong induction of NF-κB DNA-binding
activity for the time when the nuclear p65 was accumulated
in MCF-7/Adr cells (Fig. 3C).
Taken together, these results may indicate that the DOX-
treatment mediated the association of Rel A/p65 with HDAC1
in the nucleus and then promoted Rel A/p65 export from the
nucleus to the cytoplasm. In contrast, this cytoplasmic reloca-
lization of Rel A/p65 did not occur in the treatment with TNF-α
alone.3.3. Treatment of TNF-α following DOX inhibited expression of
anti-apoptotic genes
We were interested in confirming that the effects of the
intracellular trafficking of Rel A/p65 induced by HDAC1
could be seen with NF-κB/Rel A/p65-regulated target genes.
For these experiments, we analyzed c-IAP1 and Bcl-xL,
which are anti-apoptotic genes regulated by NF-κB. The
semiquantitative PCR analysis of RNA extracted from MCF-
7/Adr cells stimulated with either DOX or TNF-α revealed
increases in Bcl-xL and c-IAP1 mRNA levels. In contrast, c-
IAP1 and Bcl-xL mRNA levels remarkably decreased in
MCF-7/Adr cells with the treatment of DOX followed by
TNF-α (Fig. 4A). In contrast to these observations, DOX
treatment alone resulted in decrease in Bcl-xL and c-IAP1
mRNA levels in its parental MCF-7 cells (Fig. 4B). It led us
to suggest that MCF-7/Adr cells were more resistant to DOX
treatment may partly due to losing its ability of decreasing
expression of these anti-apoptotic genes. As a specificity
control, GAPDH mRNA expression was unaffected under
these conditions. These results suggest that the combination
of DOX and TNF-α treatment target the expression of some
anti-apoptotic genes such as c-IAP1 and Bcl-xL in both cell
lines.
3.4. Treatment of TNF-α following DOX potentiated the
activation of caspase-8
TNF-α-induced cell death requires the activation of caspase-
8. Studies were next performed to define the effects on apopto-
tic signal of caspase-8 for HDAC1-mediated nuclear export of
Rel A/p65 and the inhibition of NF-κB-induced anti-apoptotic
gene expressions. MCF-7/Adr cells were treated with TNF-α,
DOX alone, or the treatment with DOX followed by TNF-α.
The activated caspase-8 protein amounts were measured by
detecting its active 18-kDa subunit with an antibody specific
against active (cleaved) caspase-8. Comparing to treatment of
DOX or TNF-α alone, the treatment with DOX followed by
TNF-α remarkably elevated the expression of the cleaved (ac-
tive) subunit of caspase-8 (Fig. 5). There was also the correla-
tion between the extent of cell death and the activation of
caspase-8, when MCF-7/Adr cells were exposed to this treat-
ment (Figs. 1 and 5).
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In this study, we reported that the treatment of multidrug-
resistant MCF-7/Adr cells with TNF-α following DOX admin-
istrations remarkably increased the cytotoxic effect of chemo-
therapeutic agent DOX on tumor cells. This effect was
associated with the inhibition of NF-κB-induced anti-apoptotic
gene expressions and the increased activation of caspase-8. We
also demonstrated HDAC1 was involved in mediating nuclear
export of Rel A/p65.
MCF-7/Adr cell line originally came from human breast
cancer cell line MCF-7, displaying cross-resistance to many
chemotherapeutic agents. Several mechanisms including over-
expression of P-gp, GST-Px contribute to the degree of drug
resistance in MCF-7/Adr cells [18]. Moreover, Ogretmen's
group found that a 21-bp deletion beginning at exon 5 in the
tumor suppression p53 gene alters its expression levels, stabil-
ity and cellular localization of the protein in multidrug resistant
MCF-7/Adr cells [19]. Recently, several groups revealed that
MCF-7/Adr cells have different genotype and phenotypic char-
acteristics from its parental MCF-7 cells [20].
The efficiency of anticancer therapy is limited by the devel-
opment of drug resistance. Great efforts have been made to
improve the efficacy of the cytotoxic response to chemothera-
peutic agents on this drug-resistant human breast tumor [21].
TNF-α acts synergistically with cytotoxic drugs against a vari-
ety of tumor cells, and the observation that TNF-α is able to do
so in drug-resistant tumor cell lines and thereby overcomes
drug resistance is especially provocative [22–24]. In this
study, we found the treatment of TNF-α following DOX re-
versed the resistance to cytotoxic treatment in MCF-7/Adr cells
(Fig. 1). This might represent a new strategy to improve the
efficiency of therapeutic response to the tumors known to be
resistant to chemotherapy. However, it should be noted that this
combined therapy was effective in overcoming the resistance to
TNF-α rather than DOX treatment. Moreover, it had been
shown by several studies that the possible synergistic effects
of TNF-α with other drugs are strongly dependent on several
conditions such as the sequence of administration. However,
the molecular basis for that has to be well defined.
The activation of caspase-8 contributes to TNF-α-induced
cytotoxic action [25,26]. However, the activation of NF-κB
prevents TNF-α-induced cytotoxic action by blocking cas-
pase-8 with anti-apoptotic gene expressions [27]. In this
study, we found that treatment with TNF-α alone induced
modest cytotoxic effect in MCF-7/Adr cells, i.e., about 83%
survival rate after 500 U/ml TNF-α 0.5 h treatment (data not
shown). The model for NF-κB's anti-apoptotic action is that
following TNF-α stimulation of cells, which results in degra-
dation of IκBα, NF-κB is translocated to the nucleus and binds
tightly to κB-DNA elements to induce anti-apoptotic gene
expressions, such as c-IAP1, c-IAP2, TRAF1, TRAF2 and X-
IAP, whose protein products are caspase inhibitors [28]. In this
report, we demonstrate that TNF-α/DOX-treatment eliminated
NF-κB protection by HDAC1-mediating to export Rel A/p65
from the nucleus and subsequently turn off NF-κB-mediate
anti-apoptotic gene expressions. Then, cells could override theinhibition conveyed by the NF-κB pathway to carry out cell
death due to expression of elevated activated caspase 8 (Fig. 5).
Thus, translocation of Rel A/p65 from the nucleus may be a
turning point in TNF-α-induced cell death. However, more
intrinsic mechanistic studies between the two processes should
be proved and addressed in our future work.
A growing number of reports suggest that HDACs not only
deacetylate core histone leading to repressive changes in chro-
matin structure but also deacetylate various host transcription
factors, altering transcriptional activity [15–17]. In combina-
tion with other data, we suggested that after the treatment with
DOX, HDAC1 was identified as the histone deacetylase re-
sponsible for the deacetylation by it's binding to Rel A/p65. We
showed HDAC1 regulated the intracellular trafficking of Rel A/
p65 in a time-dependent pathway. After 12 h treatment of DOX,
the interaction between Rel A/p65 and HDAC1 led to the
removal of Rel A/p65 from the nucleus to the cytoplasm and
subsequently turn off NF-κB-mediate anti-apoptotic gene
expressions in MCF-7/Adr cells (Figs. 3 and 4). NH2-terminal
regions of both HDAC1 and Rel A/p65 are reported to be
required for the assembly of these two proteins in vivo.
Recently, several groups revealed that MCF-7/Adr cells
have different genotype and phenotypic characteristics from
its parental MCF-7 cells [20]. MCF-7/Adr cells contain full-
length functional caspase-3 protein, while MCF-7 cells are
caspase-3 deficient. It should be noted the activation of cas-
pase-8 may be essential for this combined treatment TNF-α/
DOX-induced cell death. As shown in Fig. 5, the combination
of TNF-α and DOX was efficient in inducing caspase-8 cleav-
age in MCF-7/Adr cells. The activated caspase-8 played an
important role in this study.
The ability of TNF-α to cause cytotoxic action in neoplastic
cells is of great interest with respect to its potential roles in
cancer therapy. The understanding of the combination of TNF-
α treatment with chemotherapeutic agents and the underlying
mechanisms might provide new strategies to overcome tumor-
drug resistance by synergistic interactions.
References
[1] E. Frei III, D. Spriggs, Tumor necrosis factor: still a promising agent,
J. Clin. Oncol. 7 (1989) 291–294.
[2] Q.H. Zhou,M.Hou, L. Li, L. Ren,M.Qiu, Y.Q.Yang,W.X.Huang, Z. Chen,
Z.Q. Meng, M.Z. Song,M.Z. Li, E.X. Li, Y. Li, Y. Yao, Z.W. Zheng, X. Liu,
X.F. Zhang, H.S. Lu, M.H. Zhang, W.X. Wang, X.J. Lu, A multicenter
randomized phase II trial of domestic product of nrh-TNF in the treatment of
non-small cell lung cancer, Chin. J. Lung Cancer 6 (2003) 42–45.
[3] Z. Chen, M.L. Liu, W.X. Huang, A clinical research on rnhTNF for 87
cases with advanced cancer, Chin. J. Clin. Oncol. 30 (2003) 877–880.
[4] E.X. Li, M.Z. Li, K.J. Nan, Randomized-controlled study of recombinant
mutant human tumor necrosis factor in advanced malignant tumor, Chin.
Oncol. 13 (2003) 353–355.
[5] F.J. Lejeune, High dose recombinant tumor necrosis factor (rTNFα)
administered by isolation perfusion for advanced tumors of limbs: a model
for biochemotherapy of cancer, Eur. J. Cancer 31 (1995) 1009–1016.
[6] A.M.M. Eggermont, H. Schraffordt Koops, D. Lienard, B.B. Kroon, A.N.
van Geel, H.J. Hoekstra, F.J. Lejeune, Isolated limb perfusion with high-
dose tumor necrosis factor-alpha in combination with interferon-gamma
and melphalan for nonresectable extremity soft tissue sarcomas: a
multicenter trial, J. Clin. Oncol. 14 (1996) 2653–2665.
187W. Cao et al. / Biochimica et Biophysica Acta 1763 (2006) 182–187[7] A.H. van der Veen, T.L.M. Ten Hagen, J.H.Y. De Wilt, M.J.A. van Ijken,
A.M.M. Eggermont, An overview on the use of TNF-alpha: our experience
with regional administration and developments towards new opportunities
for systemic application, Anticancer Res. 20 (2000) 3467–3474.
[8] S.T. Whiteside, M.K. Ernst, O. Lebail, C. Laurent-Winter, N. Rice, A.A.
Israel, N- and C-terminal sequences control degradation of MAD3/I kappa
B alpha in response to inducers of NF-kappa B activity, Mol. Cell. Biol. 15
(1995) 5339–5345.
[9] C.R. Fairchild, S.P. Ivy, C.S. Kao-Shan, J. Whang-peng, N. Rosen, M.A.
Isreal, P.W. Melera, K.H. Cowan, M.E. Goldsmith, Isolation of amplified
and overexpressed DNA sequences from adriamycin resistant human
breast cancer cells, Cancer Res. 47 (1987) 5141–5148.
[10] C.R. Fairchild, J.A. Moscow, E.E. O'Brien, K.H. Cowan, Multidrug
resistance in cells transfected with human genes encoding a variant P-
glycoprotein and glutathione S-transferase-pi, Mol. Pharmacol. 37 (1990)
801–809.
[11] Y.J. Lu, M. Tatsuka, H. Takebe, T. Yagi, Involvement of cyclin-dependent
kinases in Doxorubicin-induced apoptosis in human tumor cells, Mol.
Carcinog. 29 (2000) 1–7.
[12] Y.J. Lu, N. Yamagishi, T. Yagi, H. Takebe, Mutated p21WAF1/CIP1/SDI1
lacking CDK-inhibitory activity fails to prevent apoptosis in human
colorectal carcinoma cells, Oncogene 16 (1998) 705–712.
[13] W. Cao, W.H. Chi, J. Wang, J.J. Tang, Y.J. Lu, TNF-α promotes
Doxorubicin-induced cell apoptosis and anti-cancer effect through down-
regulation of p21 in p53-deficient tumor cells, Biochem. Biophys. Res.
Commun. 330 (2005) 1034–1040.
[14] R.U. Janicke, M.L. Sprengart, M.R. Wati, A.G. Porter, Caspase-3 is
required for DNA fragmentation and morphological changes associated
with apoptosis, J. Biol. Chem. 273 (1998) 9357–9360.
[15] K.J. Campbell, S. Rocha, N.D. Perkins, Active repression of antiapoptosis
gene expression by RelA (p65) NF-κB, Mol. Cell 13 (2004) 853–865.
[16] L.F. Chen, W.G. Fischle, E. Verdin, W.C. Greene, Duration of nuclear NF-
κB action regulated by reversible acetylation, Science 293 (2001)
1653–1657.
[17] R. Kiernan, V. Bres, R.W. Ng, M.P. Coudart, S. El Messaoudi, C. Sardet,
D.Y. Jin, S. Emiliani, M. Benkirane, Post-activation turn-off of NF-κB-
dependent transcription is regulated by acetylation of p65, J. Biol. Chem.
278 (2003) 2758–2766.
[18] W.W. Wells, P.A. Rocque, D.P. Xu, E.B. Meyer, L.J. Charamella, N.V.
Dimitrov, Ascorbic acid and cell survival of adriamycin resistant andsensitive MCF-7 breast tumor cells, Free Radical Biol. Med. 18 (1995)
699–708.
[19] B. Ogretmen, A.R. Safa, Expression of the mutated p53 tumor suppressor
protein and its molecular and biochemical characterization in multidrug
resistant MCF-7/Adr human breast cancer cells, Oncogene 14 (1997)
499–506.
[20] K. Mehta, E. Devarajan, J. Chen, A. Multani, S. Pathak, Multidrug-
resistant MCF-7 cells: an identity crisis? J. Natl. Cancer Inst. 94 (2002)
1652–1654.
[21] M. Ameyar, V. Shatrov, C. Bouquet, C. Capoulade, Z.Z. Cai, R. Stancou,
C. Badie, H. Haddada, S. Chouaib, Adenovirus-mediated transfer of wild-
type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic
effect of this cytokine: relationship with c-myc and Rb, Oncogene 18
(1999) 5464–5472.
[22] B. Bonavida, T. Tsuchitani, J. Zighelboim, J.S. Berek, Synergy is
documented in vitro with low-dose recombinant tumor necrosis factor,
cisplatin, and Doxorubicin in ovarian cancer cells, Gynecol. Oncol. 38
(1990) 333–339.
[23] J.T. Safrit, B. Bonavida, Sensitivity of resistant human tumor cell lines
to tumor necrosis factor and adriamycin used in combination:
correlation between down-regulation of tumor necrosis factor-messenger
RNA induction and overcoming resistance, Cancer Res. 52 (1992)
6630–6637.
[24] Y. Mizutani, B. Bonavida, Overcoming cis-diamminedichloroplatinum (II)
resistance of human ovarian tumor cells by combination treatment with cis-
diamminedichloroplatinum (II) and tumor necrosis factor-alpha, Cancer 72
(1993) 809–818.
[25] M. Muzio, A.M. Chinnaiyan, F.C. Kischkel, K. O'Rourke, A. Shevchenko,
J. Ni, C. Scaffidi, J.D. Bretz, M. Zhang, R. Gentz, M. Mann, P.H.
Krammer, M.E. Peter, V.M. Dixit, FLICE, a novel FADD-homologous
ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-
inducing signaling complex, Cell 85 (1996) 817–827.
[26] A. Ashkenazi, V.M. Dixit, Death receptors: signaling and modulation,
Science 281 (1998) 1305–1308.
[27] A.A. Beg, D. Baltimore, An essential role for NF-κB in preventing TNF-α-
induced cell death, Science 274 (1996) 782–784.
[28] Z.L. Chu, T.A. McKinsey, L. Liu, J.J. Gentry, M.H. Malin, D.W. Ballard,
Suppression of tumor necrosis factor-induced cell death by inhibitor of
apoptosis c-IAP2 is under NF-αB control, Proc. Natl. Acad. Sci. U. S. A.
94 (1997) 10057–10062.
